Eptifibatide

• UNSPSC Description:

  Eptifibatide is a cyclic heptapeptide, acts as a competitive antagonist for the activated platelet glycoprotein IIb/IIIa receptor, with anti-platelet activity[1].

• Target Antigen:

  Integrin

• Type:

  Peptides

• Related Pathways:

  Cytoskeleton

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/Eptifibatide.html

• Purity:

  99.96

• Solubility:

  DMSO : 200 mg/mL (ultrasonic)|H2O : 50 mg/mL (ultrasonic)

• Smiles:

  O=C(N(CCC1)[C@]1([H])C(N[C@@H](CSSCCC2=O)C(N)=O)=O)[C@](NC([C@@H](NC(CNC([C@@H](N2)CCCCNC(N)=N)=O)=O)CC(O)=O)=O)([H])CC3=CNC4=CC=CC=C34

• Molecular Weight:

  831.96

• References & Citations:

  [1]Gilchrist IC, et al. Platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention: focus on the pharmacokinetic-pharmacodynamic relationships of eptifibatide. Clin Pharmacokinet. 2003;42(8):703-20.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)

• Clinical Information:

  Launched

• CAS Number:

  188627-80-7